Squarepoint Ops LLC Sells 43,846 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Squarepoint Ops LLC lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 19.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,814 shares of the company's stock after selling 43,846 shares during the quarter. Squarepoint Ops LLC owned approximately 0.54% of TransMedics Group worth $11,398,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMDX. Braidwell LP acquired a new position in shares of TransMedics Group during the 4th quarter worth about $57,493,000. Norges Bank bought a new position in TransMedics Group during the fourth quarter worth $22,861,000. Dimensional Fund Advisors LP increased its holdings in shares of TransMedics Group by 1,565.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after purchasing an additional 253,624 shares during the last quarter. Emerald Advisers LLC raised its position in shares of TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after purchasing an additional 220,804 shares during the period. Finally, FIL Ltd raised its position in shares of TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after purchasing an additional 218,961 shares during the period. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMDX. Oppenheimer upped their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reissued an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $126.70.

TransMedics Group Stock Up 1.7%

Shares of TMDX opened at $123.34 on Friday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm's 50 day moving average is $88.46 and its 200-day moving average is $77.00. The stock has a market capitalization of $4.17 billion, a PE ratio of 131.21 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the company earned $0.35 EPS. Equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.